- Made Scientific and Streamline Bio, Inc. have launched an exclusive Early Adopter and Design Partner Programme to integrate and validate AI-driven robotic manufacturing in a GMP-ready environment.
- Made Scientific will act as Streamline Bio’s exclusive early adopter and preferred CDMO partner, supporting automated workflows and autonomous CAR-T manufacturing studies.
Made Scientific, a clinical- and commercial-enabling cell therapy CDMO, has entered an exclusive Early Adopter and Design Partner Programme with Streamline Bio, Inc., a robotics company focused on AI-driven precision automation for biomanufacturing. The collaboration centres on the co-development, integration and validation of Streamline Bio’s AI-driven robotic manufacturing platform within a GMP-ready environment.
Under the agreement, Made Scientific will serve as Streamline Bio’s exclusive early adopter, design partner and preferred CDMO partner. The companies will work to accelerate automated workflows, including new unit operations, enhanced analytics and data capture, and agentic AI-based improvements to support repeatable and scalable GMP operations. The programme will also evaluate autonomous rapid CAR-T manufacturing through end-to-end automation of critical process steps using industry-standard platforms.
Activities will be conducted within Made Scientific’s GMP manufacturing operations in Princeton, New Jersey. The studies are designed to target cycle-time optimisation, process robustness and operational scalability in cell therapy contract manufacturing. The partnership builds on a previously announced collaboration between the two organisations.
“We are pleased to formalize our role as Streamline Bio’s exclusive CDMO technology partner as they work to redefine cell therapy manufacturing through advanced AI-driven automation.”
Syed T. Husain, Chairman and CEO of Made Scientific
According to the companies, the expanded partnership aims to advance scalable, automated manufacturing solutions with the potential to streamline operations, reduce cost of goods and broaden patient access to cell therapies.
